Skip to content
Back to meeting Original
Max Kates· @MaxKates · X·· 3 days agoScore70

KEYNOTE-866

Body

Neoadjuvant MIBC Trials: KEYNOTE-866 (pembro) and ENERGIZE (nivo)negative. NIAGARA (durva) stands alone. Adjuvant is split too. ICI benefit in MIBC is real but marginal, and likely lives in a subset we have yet to identify. Utilit of chemo+IO less clear in EVP era. #ESMO26

9 views · 1 like · 0 reposts · 0 replies

Conference abstracts
4735Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study

https://esmocongress.esmo.org

Source: Max Kates · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.